Proactive Investors - Run By Investors For Investors

Neovasc announces secondary offering, aims to raise more than US$4M

The company said it will float more than 11 million common shares at a price of US$0.45 per share
Cardiovascular system surrounded by red blood cells
The company plans to use the proceeds to develop its cardiovascular treatments

Neovasc Inc (NASDAQ:NVCN) (TSE:NVCN) announced a secondary offering Wednesday of more than 11 million shares of common stock, hoping to earn net proceeds of as much US$4.25 million.

Shares of the cardiovascular medical device company are expected to be available for US$0.45 per share on March 15.

The Richmond, British Columbia-based company plans to use the proceeds to develop two of its treatments: the Reducer, which treats refractory angina, and the Tiara, which treats mitral regurgitation. Proceeds are also expected to go toward general corporate and working capital purposes.

The stock fell on news of the public offering, dropping 9.8% to close at US$0.58 in New York Wednesday and losing more than 11% after the bell to C$0.64 in Toronto. Shares were flat in Thursday's pre-market session.

--Updates share price--

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full NVC profile View Profile

Neovasc Timeline

Related Articles

January 08 2019
Its plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use